At Theradex, Dr. Anderson acts as the medical and safety monitor for commercial phase I, II and III trials. He supervises the Clinical Operations teams and helps sponsors devise strategies for new agent evaluation and protocol development. Additionally, Dr. Anderson supervises Theradex’s Clinical Trial Monitoring Service team that reviews and audits early phase studies conducted by the National Cancer Institute. In the CTMS role, Dr. Anderson interacts with staff at the NCI Clinical Trials Monitoring Branch and Cancer Therapy Evaluation Program.
Dr. Anderson joined Theradex in 2007, after serving as a Senior Investigator at the Clinical Investigations Branch of the NCI Cancer Therapy Evaluation Program for eight years. While at NCI he worked closely with extramural NCI-supported investigators in the design, conduct and oversight of phase I, II and III cancer clinical trials conducted by the NCI Cooperative Groups. He served on numerous Data Safety Monitoring Boards for national cancer trials and was a leader in the development of the NCI-supported Pediatric Central IRB. Dr. Anderson was also an assistant professor and clinical attending in the Division of Pediatric Hematology, Oncology and Stem Cell Transplant at the Lombardi Cancer Center of Georgetown University for five years prior to joining the NCI. His experience with clinical patient care and the design and implementation of large, multi-institutional cancer treatment studies has provided Dr. Anderson with significant exposure to the scientific, regulatory and clinical aspects of contemporary cancer clinical trial conduct. Dr. Anderson received a Bachelor of Science in Biology from Lehigh University, a Ph.D. in Immunology from Duke University Medical Center and his medical degree from the University of Virginia. He trained in pediatric medicine at Northwestern University and completed a fellowship in Pediatric Hematology/Oncology and HIV research at the National Cancer Institute Pediatric Branch.